108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
泰利妥塞普治疗狼疮性脂膜炎的潜力：一例报告
Authors Xie X, Tang S, Huang M
Received 9 July 2025
Accepted for publication 25 September 2025
Published 7 October 2025 Volume 2025:19 Pages 585—593
DOI https://doi.org/10.2147/BTT.S551578
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Shein-Chung Chow
Xinying Xie,1,* Shuibo Tang,1,* Ma Huang2
1Rheumatology and Immunology Department, Hunan University of Medicine General Hospital, Huaihua, Hunan, People’s Republic of China; 2Department of Intensive Care Medicine, Hunan University of Medicine General Hospital, Huaihua, Hunan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ma Huang, Email huangma19910219@163.com
Abstract: Lupus erythematosus panniculitis (LEP) is a rare and serious skin lesion associated with systemic lupus erythematosus (SLE). In the past, the management of LEP has followed the treatment guidelines for SLE, which is based on the administration of high doses of hormones together with immunosuppressants, with no treatment plans specific for LEP. However, the long-term use of high hormone doses and immunosuppressants can exacerbate skin breakage and calcification. Telitacicep is an approved biological agent demonstrating significant therapeutic efficacy in immune system disorders. We report a case of lupus erythematosus panniculitis in which the patient’s clinical symptoms and laboratory test results improved after treatment with a combination of steroids, cyclophosphamide, and the biologic agent Telitacicept. The condition was significantly controlled and alleviated. This report highlights the successful application of Telitacicept in the treatment of lupus panniculitis, providing valuable insights for future management of this condition.
Keywords: Telitacicept, biologicals, Lupus erythematosus panniculitis
1Rheumatology and Immunology Department, Hunan University of Medicine General Hospital, Huaihua, Hunan, People’s Republic of China; 2Department of Intensive Care Medicine, Hunan University of Medicine General Hospital, Huaihua, Hunan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ma Huang, Email huangma19910219@163.com
Abstract: Lupus erythematosus panniculitis (LEP) is a rare and serious skin lesion associated with systemic lupus erythematosus (SLE). In the past, the management of LEP has followed the treatment guidelines for SLE, which is based on the administration of high doses of hormones together with immunosuppressants, with no treatment plans specific for LEP. However, the long-term use of high hormone doses and immunosuppressants can exacerbate skin breakage and calcification. Telitacicep is an approved biological agent demonstrating significant therapeutic efficacy in immune system disorders. We report a case of lupus erythematosus panniculitis in which the patient’s clinical symptoms and laboratory test results improved after treatment with a combination of steroids, cyclophosphamide, and the biologic agent Telitacicept. The condition was significantly controlled and alleviated. This report highlights the successful application of Telitacicept in the treatment of lupus panniculitis, providing valuable insights for future management of this condition.
Keywords: Telitacicept, biologicals, Lupus erythematosus panniculitis